Nuwellis, Inc. (NUWE)
Automate Your Wheel Strategy on NUWE
With Tiblio's Option Bot, you can configure your own wheel strategy including NUWE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NUWE
- Rev/Share 6.0274
- Book/Share 2.4571
- PB 0.1087
- Debt/Equity 0.1374
- CurrentRatio 2.2274
- ROIC -2.0669
- MktCap 1277408.0
- FreeCF/Share -6.3765
- PFCF -0.1374
- PE -0.0396
- Debt/Assets 0.0702
- DivYield 0
- ROE -6.1007
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 5
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Nuwellis Announces Pricing of $4.3 Million Underwritten Public Offering
Published: June 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
MINNEAPOLIS, June 09, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a commercial-stage medical device company dedicated to transforming care for fluid overload patients, today announced the pricing of a public offering of 406,755 shares of its common stock (“Common Stock”), pre-funded warrants to purchase 14,085,998 shares of Common Stock, in each case with accompanying Series A Warrants to purchase up to 43,478,259 shares of Common Stock and Series B Warrants to purchase up to 14,492,753 shares of Common Stock.
Read More
Nuwellis, Inc. (NUWE) Q1 2025 Earnings Call Transcript
Published: May 13, 2025 by: Seeking Alpha
Sentiment: Neutral
Nuwellis, Inc. (NASDAQ:NUWE ) Q1 2025 Earnings Conference Call May 13, 2025 9:00 AM ET Company Participants Louisa Smith - IR, Gilmartin Group John Erb - Chairman & Interim CEO Rob Scott - CFO Conference Call Participants Jonathan Aschoff - ROTH Operator Good day, everyone, and welcome to Nuwellis First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Read More
Nuwellis, Inc. (NUWE) Reports Q1 Loss, Lags Revenue Estimates
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Negative
Nuwellis, Inc. (NUWE) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $20.98 per share a year ago.
Read More
Nuwellis Contracts with KDI Precision Manufacturing to Strengthen Production and Improve Operational Efficiency
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Strategic agreement is expected to reduce costs, preserve expertise, and streamline operations. WHO WHAT WHERE WHEN WHY Nuwellis, Inc. (Nasdaq: NUWE) and KDI Precision Manufacturing Outsourcing manufacturing and assembly of key Aquadex product components.
Read More
Nuwellis Expands Aquadex® for Pediatric Fluid Management to Two New Hospital Systems
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
MINNEAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on fluid management solutions for patients with fluid overload, today announced a meaningful step forward for children facing fluid overload with the recent expansion of its Aquadex SmartFlow® therapy into two additional pediatric centers across the Southeastern United States. The company now has 47 pediatric centers that have adopted Aquadex therapy as part of their fluid management approach.
Read More
Nuwellis, Inc. (NUWE) Q4 2024 Earnings Call Transcript
Published: March 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Nuwellis, Inc. (NASDAQ:NUWE ) Q4 2024 Earnings Conference Call March 11, 2025 9:00 AM ET Company Participants Vivian Cervantes - Gilmartin Group, Investor Relations John Erb - Interim President and Chief Executive Officer Rob Scott - Chief Financial Officer Conference Call Participants Jonathan Aschoff - Roth Anthony Vendetti - Maxim Group Operator Good morning. And welcome to Nuwellis Earnings Conference Call for the Fourth Quarter and Full Year ended December 31, 2024.
Read More
JACC: Heart Failure Paper Reports Promising Findings of Aquadex Therapy in Updated AVOID-HF Study Analysis
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
MINNEAPOLIS, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical device company focused on transforming the lives of people with fluid overload, today highlighted promising findings from an updated analysis of the AVOID-HF study, recently published in the Journal of the American College of Cardiology: Heart Failure. The analysis, led by Dr. Sean P. Pinney, Chief of Cardiology at Mount Sinai Morningside and Chief of Nephrology at Lenox Hill Hospital, Dr. Maria V. DeVita, provides new insights suggesting the potential benefits of Aquadex® SmartFlow ultrafiltration therapy in managing heart failure. The analysis found that patients treated …
Read More
About Nuwellis, Inc. (NUWE)
- IPO Date 2012-02-16
- Website https://www.nuwellis.com
- Industry Medical - Devices
- CEO Mr. John L. Erb
- Employees 38